14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $21.75 $29.07 Monday, 22nd Apr 2024 ARWR stock ended at $23.92. This is 7.12% more than the trading day before Friday, 19th Apr 2024. During the day the stock fluctuated 9.27% from a day low at $22.24 to a day high of $24.30.
90 days $21.75 $36.72
52 weeks $20.67 $42.48

Historical Arrowhead Research Corporation prices

Date Open High Low Close Volume
Sep 14, 2023 $29.55 $31.14 $29.31 $30.54 1 033 841
Sep 13, 2023 $29.11 $29.70 $29.07 $29.34 715 044
Sep 12, 2023 $29.13 $29.40 $28.56 $29.10 739 839
Sep 11, 2023 $30.25 $30.41 $29.13 $29.24 1 067 112
Sep 08, 2023 $30.25 $30.70 $29.78 $29.90 659 947
Sep 07, 2023 $29.00 $30.48 $28.82 $30.22 1 085 165
Sep 06, 2023 $28.18 $29.29 $27.74 $29.22 826 868
Sep 05, 2023 $27.74 $28.51 $27.62 $28.03 668 888
Sep 01, 2023 $27.78 $28.39 $27.75 $27.96 707 443
Aug 31, 2023 $26.78 $28.02 $26.78 $27.64 1 227 336
Aug 30, 2023 $27.15 $27.54 $26.76 $26.84 776 564
Aug 29, 2023 $27.69 $27.69 $26.94 $27.15 1 150 982
Aug 28, 2023 $27.93 $28.13 $27.34 $27.66 646 826
Aug 25, 2023 $27.85 $28.30 $26.85 $27.91 981 117
Aug 24, 2023 $28.63 $28.86 $27.99 $28.04 524 430
Aug 23, 2023 $28.43 $29.04 $28.43 $28.62 466 983
Aug 22, 2023 $28.68 $28.90 $28.18 $28.38 633 915
Aug 21, 2023 $28.26 $29.16 $27.77 $28.68 607 761
Aug 18, 2023 $28.76 $29.02 $28.24 $28.26 570 322
Aug 17, 2023 $28.95 $29.18 $28.70 $29.02 511 773
Aug 16, 2023 $29.26 $29.26 $28.81 $28.95 461 472
Aug 15, 2023 $29.15 $29.69 $28.92 $29.35 576 898
Aug 14, 2023 $28.56 $29.73 $28.00 $29.39 812 928
Aug 11, 2023 $28.79 $29.19 $28.56 $28.85 596 508
Aug 10, 2023 $29.01 $29.37 $28.65 $28.97 666 722
Click to get the best stock tips daily for free!

About Arrowhead Research Corporation

Arrowhead Research Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P... ARWR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT